| Name | CAY10566 |
| Description | CAY10566 shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM). CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively.. |
| In vitro | CAY10566 (0.0001-10 μM; 24 hours) concentration-dependently decreases Swiss 3T3 cell proliferation [3]. |
| In vivo | Upon the formation of detectable tumors, mice receive either a placebo or the SCD1 inhibitor CAY10566 (2.5 mg/kg orally twice daily). SCD1 inhibition demonstrates a more pronounced effect on Akt-driven tumors compared to Ras-driven tumors. Specifically, the average tumor volume on days 13 or 14 after treatment, compared to control tumors, was 0.5±0.04 for Akt-driven tumors and 0.67±0.05 for Ras-driven tumors (P=0.01 for Ras-Akt comparison, according to a two-tailed t-test) [4]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 24 mg/mL (61.57 mM), Sonication is recommended.
|
| Keywords | Stearoyl-CoA Desaturase (SCD) | Inhibitor | inhibit | CAY-10566 | CAY10566 | CAY 10566 |
| Inhibitors Related | Disulfiram | Methotrexate | ALDH1A3-IN-3 | Rotenone | Mycophenolate Mofetil | Ribavirin | 4-Diethylaminobenzaldehyde | Benzyl alcohol | Isomalt | Isoniazid | Sodium Oxamate | Ivosidenib |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Inhibitor Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Orally Active Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Metabolism Disease Compound Library |
United States
